secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0000950170-24-005024
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences terminates license agreement with Indiana University for HBV program
--------------------------------------------------------------------------------

- On January 11, 2024, Assembly Biosciences notified IURTC of termination of exclusive license for HBV patents including vebicorvir (VBR).
- Termination effective April 11, 2024, 90 days after notice; VBR development was discontinued in July 2022.
- Aggregate milestone payments under the license were $0.8 million; royalties ranged from 0.5% to 1.75% on net sales.
- Annual diligence maintenance fees of $0.1 million were paid, creditable against milestone payments.
- Next-generation capsid assembly modulators (CAMs) were internally discovered and not covered by the terminated license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024005024/0000950170-24-005024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024005024/asmb-20240111.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-005024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer